117 related articles for article (PubMed ID: 38536921)
21. Bioinformatic analysis of the role of solute carrier-glutamine transporters in breast cancer.
Zhao X; Jin L; Liu Y; Liu Z; Liu Q
Ann Transl Med; 2022 Jul; 10(14):777. PubMed ID: 35965834
[TBL] [Abstract][Full Text] [Related]
22. Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems.
Yokoyama Y; Estok TM; Wild R
Mol Cancer Ther; 2022 Oct; 21(10):1561-1572. PubMed ID: 35930753
[TBL] [Abstract][Full Text] [Related]
23. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer.
Best SA; Gubser PM; Sethumadhavan S; Kersbergen A; Negrón Abril YL; Goldford J; Sellers K; Abeysekera W; Garnham AL; McDonald JA; Weeden CE; Anderson D; Pirman D; Roddy TP; Creek DJ; Kallies A; Kingsbury G; Sutherland KD
Cell Metab; 2022 Jun; 34(6):874-887.e6. PubMed ID: 35504291
[TBL] [Abstract][Full Text] [Related]
24. Creatine transport and creatine kinase activity is required for CD8
Samborska B; Roy DG; Rahbani JF; Hussain MF; Ma EH; Jones RG; Kazak L
Cell Rep; 2022 Mar; 38(9):110446. PubMed ID: 35235777
[TBL] [Abstract][Full Text] [Related]
25. NRF2: KEAPing Tumors Protected.
Pillai R; Hayashi M; Zavitsanou AM; Papagiannakopoulos T
Cancer Discov; 2022 Mar; 12(3):625-643. PubMed ID: 35101864
[TBL] [Abstract][Full Text] [Related]
26. Lack of CD8
Horton BL; Morgan DM; Momin N; Zagorulya M; Torres-Mejia E; Bhandarkar V; Wittrup KD; Love JC; Spranger S
Sci Immunol; 2021 Oct; 6(64):eabi8800. PubMed ID: 34714687
[TBL] [Abstract][Full Text] [Related]
27. Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1.
Romero R; Sánchez-Rivera FJ; Westcott PMK; Mercer KL; Bhutkar A; Muir A; González Robles TJ; Lamboy Rodríguez S; Liao LZ; Ng SR; Li L; Colón CI; Naranjo S; Beytagh MC; Lewis CA; Hsu PP; Bronson RT; Vander Heiden MG; Jacks T
Nat Cancer; 2020 Jun; 1(6):589-602. PubMed ID: 34414377
[TBL] [Abstract][Full Text] [Related]
28. Interrogating in vivo T-cell metabolism in mice using stable isotope labeling metabolomics and rapid cell sorting.
Sheldon RD; Ma EH; DeCamp LM; Williams KS; Jones RG
Nat Protoc; 2021 Sep; 16(9):4494-4521. PubMed ID: 34349284
[TBL] [Abstract][Full Text] [Related]
29. Acquired Resistance to KRAS
Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
[TBL] [Abstract][Full Text] [Related]
30. Sotorasib for Lung Cancers with
Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F; Kato T; Curioni-Fontecedro A; Sacher A; Spira A; Ramalingam SS; Takahashi T; Besse B; Anderson A; Ang A; Tran Q; Mather O; Henary H; Ngarmchamnanrith G; Friberg G; Velcheti V; Govindan R
N Engl J Med; 2021 Jun; 384(25):2371-2381. PubMed ID: 34096690
[TBL] [Abstract][Full Text] [Related]
31. Interpretation of T cell states from single-cell transcriptomics data using reference atlases.
Andreatta M; Corria-Osorio J; Müller S; Cubas R; Coukos G; Carmona SJ
Nat Commun; 2021 May; 12(1):2965. PubMed ID: 34017005
[TBL] [Abstract][Full Text] [Related]
32. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
Nachef M; Ali AK; Almutairi SM; Lee SH
Front Immunol; 2021; 12():624324. PubMed ID: 33953707
[TBL] [Abstract][Full Text] [Related]
33. Improving oligo-conjugated antibody signal in multimodal single-cell analysis.
Buus TB; Herrera A; Ivanova E; Mimitou E; Cheng A; Herati RS; Papagiannakopoulos T; Smibert P; Odum N; Koralov SB
Elife; 2021 Apr; 10():. PubMed ID: 33861199
[TBL] [Abstract][Full Text] [Related]
34. Asparagine enhances LCK signalling to potentiate CD8
Wu J; Li G; Li L; Li D; Dong Z; Jiang P
Nat Cell Biol; 2021 Jan; 23(1):75-86. PubMed ID: 33420490
[TBL] [Abstract][Full Text] [Related]
35. The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies.
Varghese S; Pramanik S; Williams LJ; Hodges HR; Hudgens CW; Fischer GM; Luo CK; Knighton B; Tan L; Lorenzi PL; Mackinnon AL; McQuade JL; Hailemichael Y; Roszik J; Peng W; Vashisht Gopal YN
Mol Cancer Ther; 2021 Mar; 20(3):500-511. PubMed ID: 33361272
[TBL] [Abstract][Full Text] [Related]
36. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer.
Edwards DN; Ngwa VM; Raybuck AL; Wang S; Hwang Y; Kim LC; Cho SH; Paik Y; Wang Q; Zhang S; Manning HC; Rathmell JC; Cook RS; Boothby MR; Chen J
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33320840
[TBL] [Abstract][Full Text] [Related]
37. First-Line Lorlatinib or Crizotinib in Advanced
Shaw AT; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Solomon BJ;
N Engl J Med; 2020 Nov; 383(21):2018-2029. PubMed ID: 33207094
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of Keap1 Confers Features of a Fasted Metabolic State.
Knatko EV; Tatham MH; Zhang Y; Castro C; Higgins M; Dayalan Naidu S; Leonardi C; de la Vega L; Honda T; Griffin JL; Hay RT; Dinkova-Kostova AT
iScience; 2020 Oct; 23(10):101638. PubMed ID: 33103077
[TBL] [Abstract][Full Text] [Related]
39. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
Singh A; Daemen A; Nickles D; Jeon SM; Foreman O; Sudini K; Gnad F; Lajoie S; Gour N; Mitzner W; Chatterjee S; Choi EJ; Ravishankar B; Rappaport A; Patil N; McCleland M; Johnson L; Acquaah-Mensah G; Gabrielson E; Biswal S; Hatzivassiliou G
Clin Cancer Res; 2021 Feb; 27(3):877-888. PubMed ID: 33077574
[TBL] [Abstract][Full Text] [Related]
40. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
